Patents by Inventor Carl H. June

Carl H. June has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160130355
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Application
    Filed: January 15, 2016
    Publication date: May 12, 2016
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Patent number: 9328156
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: May 3, 2016
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Publication number: 20160046724
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.
    Type: Application
    Filed: July 21, 2015
    Publication date: February 18, 2016
    Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, NOVARTIS AG
    Inventors: Jennifer Brogdon, Eugene Choi, Hilmar Erhard Ebersbach, David Glass, Heather Huet, Carl H. June, Joan Mannick, Michael C. Milone, Leon Murphy, Gabriela Plesa, Celeste Richardson, Marco Ruella, Reshma Singh, Yongqiang Wang, Qilong Wu
  • Publication number: 20160000829
    Abstract: The present invention relates generally to the treatment of PML by infusion of activated and expanded autologous lymphocytes.
    Type: Application
    Filed: September 10, 2015
    Publication date: January 7, 2016
    Inventors: Carl H. June, Bruce L. Levine, Anne Chew, Stephen J. Schuster
  • Patent number: 9228172
    Abstract: The present invention provides methods and compositions for converting non-Tregs into Tregs. The converted Tregs are referred to as inducible Tregs (iTregs). The iTregs are useful for preventing, suppressing, blocking or inhibiting an immune response. For example the iTregs are useful for preventing rejection of a transplanted tissue in a human or other animal host, or protecting against graft vs host disease. The iTregs can also be used to treat autoimmune diseases.
    Type: Grant
    Filed: June 19, 2009
    Date of Patent: January 5, 2016
    Assignees: The Trustees of the University of Pennsylvania, Regents of the University of Minnesota
    Inventors: James L. Riley, Carl H. June, Bruce R. Blazar, Keli Hippen
  • Publication number: 20150342994
    Abstract: The invention includes compositions and methods for generating and expanding therapeutic Th17 cells. The invention includes contacting T cells with a composition comprising a first agent that is capable of providing a primary activation signal to T cells and a second agent that is capable of activating ICOS on T cells in the presence of Th-17 polarizing agents.
    Type: Application
    Filed: August 11, 2015
    Publication date: December 3, 2015
    Inventors: James L. Riley, Chrystal Paulos, Carl H. June, Bruce L. Levine
  • Publication number: 20150322169
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes administering a T cell, genetically modified to express a chimeric antigen receptor (CAR), a bispecific antibody, or a combination thereof to a subject. The CAR and bispecific antibody of the invention can comprise a human antibody, a humanized antibody, or antigen-binding fragments thereof.
    Type: Application
    Filed: July 12, 2013
    Publication date: November 12, 2015
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Yangbing Zhao, Xiaojun Liu
  • Patent number: 9161971
    Abstract: The present invention relates generally to the treatment of PML by infusion of activated and expanded autologous lymphocytes.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: October 20, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce Levine, Anne Chew, Stephen J. Schuster
  • Publication number: 20150290244
    Abstract: The present invention provides compositions and methods for inducing tolerance in a human. The invention includes administering a genetically modified T cell expressing a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Application
    Filed: July 12, 2013
    Publication date: October 15, 2015
    Inventors: Carl H. June, Bruce L. Levine, Michael D. Kalos
  • Publication number: 20150283178
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.
    Type: Application
    Filed: April 7, 2015
    Publication date: October 8, 2015
    Inventors: Carl H. June, David L. Porter, Marcela Maus, Mariusz Wasik, Saar Gill, Joseph Fraietta, Marco Ruella, John Byrd, Jason Dubovsky, Amy Johnson, Natarajan Muthusamy, Saad Kenderian, Joan Mannick, David Glass, Leon Murphy, Jennifer Brogdon, William Raj Sellers
  • Patent number: 9133436
    Abstract: The invention includes compositions and methods for generating and expanding therapeutic Th17 cells. The invention includes contacting T cells with a composition comprising a first agent that is capable of providing a primary activation signal to T cells and a second agent that is capable of activating ICOS on T cells in the presence of Th-17 polarizing agents.
    Type: Grant
    Filed: February 4, 2011
    Date of Patent: September 15, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: James L. Riley, Chrystal Paulos, Carl H. June, Bruce Levine
  • Patent number: 9101584
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: August 11, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Patent number: 9102761
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: August 11, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Patent number: 9102760
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: August 11, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Publication number: 20150202286
    Abstract: The present invention provides compositions and methods for treating cancer in a patient. In one embodiment, the method comprises a first-line therapy comprising administering to a patient in need thereof a genetically modified T cell expressing a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain and monitoring the levels of cytokines in the patient post T cell infusion to determine the type of second-line of therapy appropriate for treating the patient as a consequence of the presence of the CAR T cell in the patient.
    Type: Application
    Filed: July 12, 2013
    Publication date: July 23, 2015
    Applicant: The Children's Hospital of Philadelphai
    Inventors: Carl H. June, Bruce L. Levine, Michael D. Kalos, Stephan Grupp
  • Publication number: 20150190428
    Abstract: The invention relates to of analyzing vector supernatants useful for transducing T cells destined for administration to a human subject. The invention also related to methods of analyzing transduced T cells destined for administration to a human subject.
    Type: Application
    Filed: July 12, 2013
    Publication date: July 9, 2015
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce L. Levine, Michael D. Kalos
  • Publication number: 20150140019
    Abstract: The present invention provides compositions and methods for inhibiting the depletion of healthy tissue during CAR T cell therapy. In another embodiment, the invention includes a drug-molecule conjugate which is administered to a subject receiving CAR T cell therapy, where the conjugate binds to the CAR resulting in internalization of the conjugate and inhibition of T cell activity and/or death of the T cell.
    Type: Application
    Filed: July 12, 2013
    Publication date: May 21, 2015
    Inventors: Carl H. June, Bruce L. Levine, Michael D. Kalos
  • Publication number: 20150118202
    Abstract: The present invention provides compositions and methods for treating cancer in a human.
    Type: Application
    Filed: December 12, 2014
    Publication date: April 30, 2015
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Publication number: 20150099299
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Application
    Filed: December 12, 2014
    Publication date: April 9, 2015
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Publication number: 20150093822
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Application
    Filed: December 11, 2014
    Publication date: April 2, 2015
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone